[go: up one dir, main page]

TW200619227A - Mutant interleukin-15-containing compositions and suppression of an immune response - Google Patents

Mutant interleukin-15-containing compositions and suppression of an immune response

Info

Publication number
TW200619227A
TW200619227A TW094127391A TW94127391A TW200619227A TW 200619227 A TW200619227 A TW 200619227A TW 094127391 A TW094127391 A TW 094127391A TW 94127391 A TW94127391 A TW 94127391A TW 200619227 A TW200619227 A TW 200619227A
Authority
TW
Taiwan
Prior art keywords
suppression
immune response
containing compositions
mutant interleukin
heart
Prior art date
Application number
TW094127391A
Other languages
English (en)
Inventor
Xin-Xiao Zheng
Terry B Strom
Thomas Moll
Original Assignee
Hoffmann La Roche
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Beth Israel Hospital filed Critical Hoffmann La Roche
Publication of TW200619227A publication Critical patent/TW200619227A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW094127391A 2004-08-11 2005-08-11 Mutant interleukin-15-containing compositions and suppression of an immune response TW200619227A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60047804P 2004-08-11 2004-08-11
US60104204P 2004-08-11 2004-08-11

Publications (1)

Publication Number Publication Date
TW200619227A true TW200619227A (en) 2006-06-16

Family

ID=35839987

Family Applications (2)

Application Number Title Priority Date Filing Date
TW094127391A TW200619227A (en) 2004-08-11 2005-08-11 Mutant interleukin-15-containing compositions and suppression of an immune response
TW094127389A TW200613552A (en) 2004-08-11 2005-08-11 Mutant interleukin-15 polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW094127389A TW200613552A (en) 2004-08-11 2005-08-11 Mutant interleukin-15 polypeptides

Country Status (4)

Country Link
US (2) US20060057102A1 (zh)
AR (2) AR050293A1 (zh)
TW (2) TW200619227A (zh)
WO (2) WO2006017853A2 (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
TW200619227A (en) * 2004-08-11 2006-06-16 Hoffmann La Roche Mutant interleukin-15-containing compositions and suppression of an immune response
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
JP5709356B2 (ja) 2006-01-13 2015-04-30 アメリカ合衆国 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
EP1921452A1 (en) * 2006-11-08 2008-05-14 Medizinische Hochschule Hannover Method for the diagnosis of leukemia
KR100888022B1 (ko) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US20110020269A1 (en) * 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
AU2008269032B2 (en) 2007-06-27 2013-12-05 Novartis Ag Complexes of IL-15 and IL-15Ralpha and uses thereof
CA2799608C (en) * 2009-05-28 2023-02-28 Richard H. Weisbart Amino acid sequences which enhance peptide conjugate solubility
NZ714757A (en) 2009-08-14 2018-07-27 Us Gov Health & Human Services Use of il-15 to increase thymic output and to treat lymphopenia
CA2925201A1 (en) * 2013-09-24 2015-04-02 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
CA2963989A1 (en) * 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
EP3350205A1 (en) * 2015-09-16 2018-07-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
US12233104B2 (en) 2015-10-08 2025-02-25 Nektar Therapeutics Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
US20180360977A1 (en) * 2015-12-21 2018-12-20 Armo Biosciences, Inc. Interleukin-15 Compositions and Uses Thereof
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
SI3558369T1 (sl) * 2016-12-21 2025-06-30 Cephalon Llc Protitelesa, ki se specifično vežejo na človeški il-15, in njihova uporaba
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US12036283B2 (en) 2017-05-15 2024-07-16 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
TW202442671A (zh) 2018-02-26 2024-11-01 美商欣爍克斯公司 Il-15結合物及其用途
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
KR20220012296A (ko) 2019-05-20 2022-02-03 싸이튠 파마 암 또는 감염성 질환 치료를 위한 IL-2/IL-15Rβγ 작용제 투여 요법
US20230028399A1 (en) * 2020-01-13 2023-01-26 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
US20230390361A1 (en) 2020-10-26 2023-12-07 Cytune Pharma Il-2/il-15r-beta-gamma agonist for treating squamous cell carcinoma
KR20230096047A (ko) 2020-10-26 2023-06-29 싸이튠 파마 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제
CN117597355A (zh) 2021-06-23 2024-02-23 赛腾制药 白细胞介素15变体
CA3225815A1 (en) 2021-08-13 2023-02-16 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
CN113956346B (zh) * 2021-10-26 2024-03-01 西安龙腾景云生物科技有限公司 一种重组白介素-15变体
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
US20250243279A1 (en) 2023-10-17 2025-07-31 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
CA2252557A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15
US6451308B1 (en) * 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
TW200619227A (en) * 2004-08-11 2006-06-16 Hoffmann La Roche Mutant interleukin-15-containing compositions and suppression of an immune response
AU2005335217A1 (en) * 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of B cell proliferation by IL-15

Also Published As

Publication number Publication date
US20060057102A1 (en) 2006-03-16
TW200613552A (en) 2006-05-01
AR050293A1 (es) 2006-10-11
AR050693A1 (es) 2006-11-15
WO2006020849A3 (en) 2006-10-05
WO2006017853A2 (en) 2006-02-16
US20060057680A1 (en) 2006-03-16
WO2006017853A3 (en) 2007-01-04
WO2006020849A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
TW200619227A (en) Mutant interleukin-15-containing compositions and suppression of an immune response
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
MX2009001188A (es) Compuestos quimicos.
WO2009148915A3 (en) Methods for predicting patient response to modulation of the co-stimulatory pathway
WO2007030810A3 (en) Multiparameter whole blood monitor and method
HUP0303332A2 (hu) Beültetett szerv vagy szövet ("graft") kilökődését szuppresszáló hatóanyagok
EA033415B1 (ru) Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
ZA200704247B (en) Stress tolerant cotton plants
EP4219566A3 (en) Recombinant rsv antigens
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
AU2011338647A8 (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MX2007008379A (es) Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
MY148276A (en) Long-term feed- elderly
SI1610787T1 (sl) Sinergistična kombinacija, ki obsega roflumilastin antiholinergično sredstvo, izbrano izmed tiotropijevih soli, za zdravljenje respiratornih bolezni
NO20064964L (no) Behandling av svekket respiratorisk funksjon
TW200420554A (en) A intra-airway administrating preparation
MXPA05010161A (es) Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
WO2004090095A3 (en) Generation of human regulatory t cells by bacterial toxins for the treatment of inflammatory disorders
UA87515C2 (ru) Фармацевтическая композиция толтеродина с пролонгированным высвобождением
UA86802C2 (ru) Комбинация симетикона и бисакодила для предрасположенных к запору пациентов, которые страдают от ощущения вздутия живота
UA83018C2 (uk) Комбінація рофлуміласту і формотеролу для лікування захворювань дихальних шляхів
MX2010004025A (es) Antagonistas de glucosaminoglicano basados en sdf-1 y metodos de uso de los mismos.